PR

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

August 28, 2026

Immuron Reports FY26 Preliminary Results

Immuron Reports FY26 Preliminary Results

August 28, 2026

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

August 28, 2026

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

August 28, 2026

Jiayin Group Inc. Reports Second Quarter 2026 Unaudited Financial Results

Jiayin Group Inc. Reports Second Quarter 2026 Unaudited Financial Results

August 28, 2026

Netcapital Inc. Announces Receipt of Nasdaq Notification Regarding Delayed Annual Report on Form 10-K

Netcapital Inc. Announces Receipt of Nasdaq Notification Regarding Delayed Annual Report on Form 10-K

August 28, 2026

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

August 28, 2026

GCL Announces $10 Million Share Repurchase Program

GCL Announces $10 Million Share Repurchase Program

August 28, 2026

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

August 28, 2026

Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

August 28, 2026

« 1 … 8 9 10 11 12 … 2,257 »